Leadiant is fined 10 million euros for overestimate of the prices of a rare disease medicine

The national commission on the markets and the competition Spain (Comisión Nacional de los Mercados y la Competencia, CNMC) fined Leadiant 10,25 million euros for abuse of a dominant position (violation of Art. 2 of the Law Spain about the competition and Art. 102 of the Contract about functioning of EU). Pharmaceutical company is only in the country the supplier of a preparation for treatment of a rare disease of an exchange of substances (tserebrotendinozny ksantomatoz, CTX) and overstated the prices this medicine for National health system Spain (National Health System, NHS). Besides, Leadiant...